Vaxxinity Appoints Jason Pesile as SVP, Finance & Accounting, and George Hornig to Board of Directors
January 04 2022 - 7:00AM
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the
development of a new class of immunotherapeutic vaccines, today
announced the appointment of Jason Pesile, MBA, CPA, as Senior Vice
President, Finance & Accounting. The Company also announced
today the appointment of George Hornig, Chairman of Xometry, to its
Board of Directors.
Mr. Hornig will be the new independent director to chair the
Audit Committee, with current Board members Greg Blatt and Peter
Diamandis moving to chair the Compensation Committee and Nominating
and Governance Committee, respectively.
“We are thrilled to welcome Jason to our management team and
George to the Vaxxinity Board,” said Mei Mei Hu, Chief Executive
Officer of Vaxxinity. “Jason is a well-regarded financial industry
leader with expertise managing financial functions within the
biopharmaceutical sector and will undoubtedly help us operationally
as we continue advancing multiple vaccine candidates through
clinical development. The addition of George to our Board of
Directors further strengthens our leadership team by bringing
nearly 40 years of senior executive-level experience at large,
global financial institutions to Vaxxinity.”
Mr. Pesile is a seasoned finance executive with 20 years of
experience in the biopharmaceutical space and most recently served
as Vice President Finance, Corporate Controller at BeyondSpring
Pharmaceuticals. He has worked at multiple biopharma companies
in the past 10 years, where he led various aspects of financial
operations, including accounting, financial reporting, audit and
financial planning. Earlier in his career, Jason worked in
management consulting and as a global project manager at
Schering-Plough and Merck focused on post-merger
integration. Jason graduated from the Wharton School of the
University of Pennsylvania with a B.S. degree in Finance and holds
an MBA from Columbia Business School. He is a certified public
accountant in the State of New Jersey.
Mr. Hornig is currently Chairman of Xometry (Nasdaq: XMTR), an
AI-driven platform for on-demand manufacturing of industrial parts,
and Co-Chairman (and Audit Chairman) of Healthwell Acquisition
Corp., a special purpose acquisition company. Mr. Hornig is also
Managing Partner and Co-Founder of The Seed Lab, an early-stage
venture fund. From 2010-2016, Mr. Hornig was Senior Managing
Director and COO of PineBridge Investments (formerly AIG Investment
Management). Prior to joining PineBridge, Mr. Hornig spent 11 years
at Credit Suisse Asset Management as Managing Director and Global
COO. From 1993-1999, Mr. Hornig was Executive Vice President of
Deutsche Bank Americas. Earlier in his career Mr. Hornig was
Managing Director and COO of Wasserstein Perella & Co., worked
in the M&A group of First Boston and was an Associate with the
law firm of Skadden, Arps, Slate, Meagher & Flom LLP. During
his career, Mr. Hornig has served as a Director of Forrester
Research, Unity Mutual Life, Veridian Group, KBL Merger Corp IV,
Office Tiger, Daily Candy and Merchants Preferred. Mr. Hornig
received his A.B., J.D. and M.B.A. from Harvard University.
About Vaxxinity
Vaxxinity, Inc. is purpose-driven biotechnology company
committed to democratizing healthcare across the globe. The company
is pioneering a new class of synthetic, peptide-based
immunotherapeutic vaccines aimed at disrupting the existing
treatment paradigm for chronic disease, increasingly dominated by
monoclonal antibodies, which suffer from prohibitive costs and
cumbersome administration. The company’s proprietary technology
platform has enabled the innovation of novel pipeline candidates
designed to bring the efficiency of vaccines to the treatment of
chronic diseases, including Alzheimer’s, Parkinson’s, migraine, and
hypercholesterolemia. The technology is also implemented as part of
a COVID-19 vaccine program. Vaxxinity has optimized its pipeline to
achieve a potentially historic, global impact on human health.
Forward-looking Statement
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. The use of certain words, including "believe," "may,"
“continue,” “advancing,” “potentially,” and "will" and similar
expressions, are intended to identify forward-looking statements.
These forward-looking statements involve substantial risks and
uncertainties, including statements that are based on the current
expectations and assumptions of Vaxxinity’s management about the
development of a new class of immunotherapeutic vaccines and the
innovation and efficacy of Vaxxinity’s product candidates. Various
important factors could cause actual results or events to differ
materially from those that may be expressed or implied by our
forward-looking statements. Additional important factors to be
considered in connection with forward-looking statements are
described in the "Risk Factors" section of the Company's Quarterly
Report on Form 10-Q filed with the Securities and Exchange
Commission on December 23, 2021. The forward-looking statements are
made as of this date and Vaxxinity does not undertake any
obligation to update any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
Investor ContactClaudia Styslinger
vaxxinity@argotpartners.com
Press ContactPhilip
Cowdellmedia@vaxxinity.com
Xometry (NASDAQ:XMTR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Xometry (NASDAQ:XMTR)
Historical Stock Chart
From Sep 2023 to Sep 2024